R&D Spending Showdown: AstraZeneca PLC vs Pharming Group N.V.

AstraZeneca vs Pharming: R&D Spending Trends Unveiled

__timestamp	AstraZeneca PLC	Pharming Group N.V.
Wednesday, January 1, 2014	5579000000	14182353
Thursday, January 1, 2015	5997000000	15503028
Friday, January 1, 2016	5890000000	16183585
Sunday, January 1, 2017	5757000000	22382849
Monday, January 1, 2018	5932000000	33038206
Tuesday, January 1, 2019	5958000000	31777040
Wednesday, January 1, 2020	5991000000	41464134
Friday, January 1, 2021	9736000000	67178053
Saturday, January 1, 2022	9762000000	52531000
Sunday, January 1, 2023	10935000000	68914000
Monday, January 1, 2024	13583000000

Unlocking the unknown

R&D Spending: A Tale of Two Pharmaceutical Giants

In the competitive world of pharmaceuticals, research and development (R&D) spending is a key indicator of innovation and future growth. Over the past decade, AstraZeneca PLC and Pharming Group N.V. have shown contrasting trajectories in their R&D investments. AstraZeneca, a global leader, has consistently increased its R&D spending, peaking at approximately $10.9 billion in 2023, a remarkable 96% increase from 2014. In contrast, Pharming Group N.V., a smaller player, has seen its R&D expenses grow from $14 million in 2014 to nearly $69 million in 2023, a substantial 387% rise. This stark difference highlights the scale and ambition of AstraZeneca compared to the nimble, yet rapidly growing, Pharming Group. As the pharmaceutical landscape evolves, these investments will likely shape the future of healthcare innovations.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025